## Nicolas Barry Delongchamps

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/396250/publications.pdf

Version: 2024-02-01

30 papers 1,618 citations

759233 12 h-index 27 g-index

30 all docs 30 docs citations

times ranked

30

2316 citing authors

#	Article	IF	Citations
1	Perspectives on the urological care in Parkinson's disease patients. Archivio Italiano Di Urologia Andrologia, 2022, 94, 107-117.	0.8	4
2	Head-to-head comparison of prostatic urethral lift and water vapor thermal therapy for the treatment of symptomatic benign prostatic hyperplasia: a real-life study. International Urology and Nephrology, 2021, 53, 1757-1763.	1.4	10
3	Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial. PLoS ONE, 2021, 16, e0252040.	2.5	8
4	Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer. Scientific Reports, 2020, 10, 16641.	3.3	10
5	Giant Primary Scrotal Lipoma: A Rare Entity with Diagnostic Pitfalls. Case Reports in Urology, 2020, 2020, 1-3.	0.3	5
6	Microcalcifications, calcium-sensing receptor, and cancer. Cell Calcium, 2019, 82, 102051.	2.4	8
7	PLEKHS1: A new molecular marker predicting risk of progression of non‑muscle‑invasive bladder cancer. Oncology Letters, 2019, 18, 3471-3480.	1.8	10
8	Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncology, The, 2019, 20, 100-109.	10.7	701
9	Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial. World Journal of Urology, 2018, 36, 921-929.	2.2	5
10	Impact of body mass index on the oncological outcomes of patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. World Journal of Urology, 2018, 36, 65-71.	2.2	14
11	Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment?. European Urology Focus, 2018, 4, 760-767.	3.1	26
12	Impact of body mass index on the oncological outcomes of patients treated with radical cystectomy for muscle-invasive bladder cancer. World Journal of Urology, 2017, 35, 229-235.	2.2	25
13	mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer. Oncolmmunology, 2017, 6, e1358330.	4.6	15
14	Identification of a prognostic molecular signature composed of 3 genes involved in immunity in muscle-invasive bladder cancer Journal of Clinical Oncology, 2017, 35, e16029-e16029.	1.6	0
15	Are Magnetic Resonance Imaging-Transrectal Ultrasound GuidedÂTargeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer?. Journal of Urology, 2016, 196, 1069-1075.	0.4	37
16	High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation. Oncology Letters, 2016, 11, 1375-1381.	1.8	11
17	Gleason Score Determination with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Guided Prostate Biopsies—Are We Gaining in Accuracy?. Journal of Urology, 2016, 195, 88-93.	0.4	35
18	TMPRSS2–ERG fusion transcripts expression in patients referred for prostate biopsy: combining detection in urine and needle rinse material. World Journal of Urology, 2015, 33, 807-811.	2.2	1

#	Article	IF	CITATIONS
19	Detection of Significant Prostate Cancer with Magnetic Resonance Targeted Biopsies—Should Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Guided Biopsies Alone be a Standard of Care?. Journal of Urology, 2015, 193, 1198-1204.	0.4	76
20	Integrated US-MR fusion images and MR targeted biopsies. What are their role and value in the detection and follow-up of prostate cancer. Archivos Espanoles De Urologia, 2015, 68, 349-53.	0.2	2
21	Prebiopsy Magnetic Resonance Imaging and Prostate Cancer Detection: Comparison of Random and Targeted Biopsies. Journal of Urology, 2013, 189, 493-499.	0.4	248
22	Prospective comparison of scar-related satisfaction and quality of life after laparoscopic versus open radical prostatectomy: no differences from patients' point of view. World Journal of Urology, 2013, 31, 389-393.	2.2	3
23	Re: Role of Magnetic Resonance Imaging Before Initial Biopsy: Comparison of Magnetic Resonance Imaging–Targeted and Systematic Biopsy for Significant Prostate Cancer Detection. European Urology, 2012, 61, 622-623.	1.9	5
24	Re: Prostatic Urethral Lift: Two-year Results After Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. European Urology, 2012, 62, 350-351.	1.9	5
25	Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2â€weighted, dynamic contrastâ€enhanced and diffusionâ€weighted imaging. BJU International, 2011, 107, 1411-1418.	2.5	278
26	Unstable angina following intracavernous injection of alprostadil: a case study. BMJ Case Reports, 2009, 2009, bcr0320091658-bcr0320091658.	0.5	2
27	Role of vascular endothelial growth factor in prostate cancer. Urology, 2006, 68, 244-248.	1.0	36
28	Outcome of Patients with Fortuitous Prostate Cancer after Radical Cystoprostatectomy for Bladder Cancer. European Urology, 2005, 48, 946-950.	1.9	38
29	A Challenging Case of Ureteroiliac Artery Fistula Managed With an Endovascular Approach. Vascular and Endovascular Surgery, 0, , 153857442211058.	0.7	0
30	Comparison of oncological, surgical, and functional outcomes between radical retropubic and radical perineal prostatectomy: A multi-institutional study. Urologia, 0, , 039156032211112.	0.7	0